The authors have developed a new
dosage-form using a water soluble anticancer
drug,
Bleomycin (BLM), which had prolonged releasing properties exceeding for 15 days in vivo for intracranial administration. Basic experiments using these
tablets have been previously reported. This study evaluates the anti-
cancer effect of the
tablets and its clinical application. For the evaluation of the anti-
cancer effect,
glioma cells were transplanted into the peritoneal cavity of Wister rats. The rats were divided into 4 main groups and treated by as follows: 1) BLM
tablets (1 mg.P) implantation in the peritoneal cavity, 2) Placebo implantation, 3)
Bleomycin solution (total 1 mg. P) injection and 4) physiological
saline solution injection (The control). The group treated with BLM
tablets showed the best results. Clinical application of BLM
tablets was performed in 6 patients of
craniopharyngioma. During operation, the
tablets were placed into
tumor cavity by alon-alpha. In one case, recurrence was greatly prolonged. This
tablet is considered to usable for the treatment of
cancer in not only the field of neurosurgery but also in other fields.